SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
| Condition(s) | Neisseria Gonorrhoeae Infection |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting. |
| Who can participate | Inclusion Criteria: * English speaking * Have access to the internet (via computer or phone) on at least a weekly basis * Asymptomatic (as defined below) Exclusion Criteria: * Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment. * Antibiotic use within the last 2 weeks * Contact to syphilis * Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return * Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded. * Known allergy to ci |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Washington |
| Locations | Seattle, Washington, United States |
| Start date | 2022-03-03 |
| NCT ID | NCT05286931 |
| Official listing | https://clinicaltrials.gov/study/NCT05286931 |